The Pacific Journal of Oncology & Immunotherapy (PJOI), pISSN: 3068-3149, eISSN: 3067-8110 published by American Science Press LLC, USA, is a leading international, open-access, double-blind, peer-reviewed journal dedicated to advancing research in the fields of oncology and immunotherapy. The journal aims to provide a platform for the dissemination of cutting-edge scientific research, clinical studies, and reviews that contribute to the ongoing progress in cancer treatment and immune-based therapies. PJOI covers a wide range of topics, including cancer biology, immune checkpoint inhibitors, CAR-T therapies, cancer vaccines, and the integration of immunotherapy with conventional treatment methods like chemotherapy and radiotherapy. PJOI seeks to foster global collaboration among researchers, clinicians, and healthcare professionals by publishing high-quality, unbiased content that bridges the gap between laboratory research and clinical applications. Its open-access format ensures that its content is freely accessible to a global audience, promoting knowledge-sharing and advancing the field of oncology and immunotherapy worldwide. The journal maintains a rigorous peer-review process, ensuring that only scientifically sound and impactful studies are published. Focusing on innovative research and translational studies, PJOI plays a vital role in shaping the future of cancer care, improving patient outcomes, and contributing to the development of personalized treatments that address the challenges of modern oncology.